Expression of Ral GTPases, their effectors, and activators in human bladder cancer

Clinical Cancer Research

Volumn 13, Issue 13, 2007, Pages 3803-3813

  Smith, Steven Christopher ^a   Oxford, Gary ^a   Baras, Alexander S ^a   Owens, Charles ^a   Havaleshko, Dmytro ^a   Brautigan, David L ^a   Safo, Martin K ^c   Theodorescu, Dan ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; COMPLEMENTARY DNA; FILAMIN A; GUANOSINE TRIPHOSPHATASE; HRAS PROTEIN; MESSENGER RNA; MUTANT PROTEIN; PHOSPHOTRANSFERASE; PROTEIN DERIVATIVE; RAL A PROTEIN; RAL B PROTEIN; RAL BP1 PROTEIN; RAL PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER TISSUE; EMBRYO; GENE MUTATION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOMA; MAJOR CLINICAL STUDY; MITOSIS; MODEL; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PARALOGY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; SEMINOMA; STATISTICAL SIGNIFICANCE;

ALLELES; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; MODELS, GENETIC; MODELS, MOLECULAR; MUTATION; PROTEIN CONFORMATION; RAL GTP-BINDING PROTEINS; TISSUE DISTRIBUTION; URINARY BLADDER NEOPLASMS;

EID: 34447133481     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2419     Document Type: Article

References (48)

1. Feig LA. Ral-GTPases: approaching their 15 minutes of fame. Trends Cell Biol 2003;13:419-25.
2. Ward Y, Wang W, Woodhouse E, Linnoila I, Liotta L, Kelly K. Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways. Mol Cell Biol 2001; 21:5958-69.
3. Tchevkina E, Agapova L, Dyakova N, Martinjuk A, Komelkov A, Tatosyan A. The small G-protein RalA stimulates metastasis of transformed cells. Oncogene 2005;24:329-35.
4. Oxford G, Theodorescu D. Ras superfamily monomeric G proteins in carcinoma cellmotility. Cancer Lett 2003;189:117-28.
5. Ryu CH, Kim SW, Lee KH, et al. The merlin tumor suppressor interacts with Ral guanine nucleotide dissociation stimulator and inhibits its activity. Oncogene 2005;24:5355-64.
6. Rangarajan A, Hong SJ, Gifford A, Weinberg RA. Species- and cell type-specific requirements for cellular transformation. Cancer Cell 2004;6:171-83.
7. Hamad NM, Elconin JH, Karnoub AE, et al. Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev 2002;16:2045-57.
8. Lim KH, Baines AT, Fiordalisi JJ, et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005;7:533-45.
9. Gildea JJ, Harding MA, Seraj MJ, Gulding KM, Theodorescu D. The role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer Res 2002;62:982-5.
10. Oxford G, Owens CR, Titus BJ, et al. RalA and RalB: antagonistic relatives in cancer cell migration. Cancer Res 2005;65:7111-20.
11. Rosse C, Hatzoglou A, Parrini MC, White MA, Chavrier P, Camonis J. RalB mobilizes the exocyst to drive cell migration. Mol Cell Biol 2006;26:727-34.
12. Wu JC, Chen TY, Yu CT, et al. Identification of V23RalA-Ser194 as a critical mediator for Aurora-A-induced cellular motility and transformation by small pool expression screening. J Biol Chem 2005;280: 9013-22.
13. Smith SC, Oxford G, Wu Z, et al. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 2006;66:1917-22.
14. Shackleton M, Vaillant F, Simpson KJ, et al. Generation of a functional mammary gland from a single stem cell. Nature 2006;439:84-8.
15. Titus B, Frierson HF, Jr., Conaway M, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005;65:7320-7.
16. Nicholson BE, Frierson HF, Conaway MR, et al. Profiling the evolution of human metastatic bladder cancer. Cancer Res 2004;64:7813-21.
17. Dyrskjot L, Kruhoffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004;64: 4040-8.
18. Barrett T, Suzek TO, Troup DB, et al. NCBI GEO: mining millions of expression profiles - database and tools. Nucleic Acids Res 2005;33:D562-6.
19. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
20. Theodorescu D, Laderoute KR, Gulding KM. Epidermal growth factor receptor-regulated human bladder cancer motility is in part a phosphatidylinositol 3-kinase-mediated process. Cell Growth Differ 1998; 9:919-28.
21. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005;24:5218-25.
22. Sen S, Zhou H, Zhang RD, et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 2002;94:1320-9.
23. Fukai S, Matern HT, Jagath JR, Scheller RH, Brunger AT. Structural basis of the interaction between RalA and Sec5, a subunit of the sec6/8 complex. EMBO J 2003;22:3267-78.
24. Nicely NI, Kosak J, de Serrano V, Mattos C. Crystal structures of Ral-GppNHp and Ral-GDP reveal two binding sites that are also present in Ras and Rap. Structure 2004;12:2025-36.
25. Wolthuis RM, de Ruiter ND, Cool RH, Bos JL. Stimulation of gene induction and cell growth by the Ras effector Rlf. EMBO J1997;16:6748-61.
26. Awasthi S, Sharma R, Yang Y, et al. Transport functions and physiological significance of 76 kDa Ral-binding GTPase activating protein (RLIP76). Acta Biochim Pol 2002;49:855-67.
27. Ohta Y, Suzuk i N, Nakamura S, Hartwig JH, Stossel TP. The small GTPase RalA targets filamin to induce filopodia. Proc Natl Acad Sci U S A 1999;96: 2122-8.
28. Camonis JH, White MA. Ral GTPases: corrupting the exocyst in cancer cells. Trends Cell Biol 2005;15: 327-32.
29. Luo JQ, Liu X, Hammond SM, et al. RalA interacts directly with the Arf-responsive, PIP2-dependent phospholipase D1. Biochem Biophys Res Commun 1997;235:854-9.
30. Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 2003;100: 14229-34.
31. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
32. Gildea JJ, Golden WL, Harding MA, Theodorescu D. Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer 2000;27: 252-63.
33. Harding MA, Arden KC, Gildea JW, et al. Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling. Cancer Res 2002; 62:6981-9.
34. Theodorescu D, Cornil I, Fernandez BJ, Kerbel RS. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc Natl Acad Sci U S A 1990;87:9047-51.
35. Xu L, Frankel P, Jackson D, et al. Elevated phospholipase D activity in H-Ras- but not K-Ras-transformed cells by the synergistic action of RalA and ARF6. Mol Cell Biol 2003;23:645-54.
36. Yan J, Roy S, Apolloni A, Lane A, Hancock JF. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem 1998;273: 24052-6.
37. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003;3:11-22.
38. Gonzalez-Garcia A, Pritchard CA, Paterson HF, Mavria G, Stamp G, Marshall CJ. RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell 2005;7:219-26.
39. Zhang ZT, Pak J , Huang HY, et al. Role of Haras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001;20: 1973-80.
40. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22:451-64.
41. Lim KH, Counter CM. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 2005;8:381-92.
42. Yadav S, Singhal SS, Singhal J, et al. Identification of membrane-anchoring domains of RLIP76 using deletion mutant analyses. Biochemistry 2004;43: 16243-53.
43. Singhal SS, Yadav S, Singhal J, Zajac E, Awasthi YC, Awasthi S. Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin. Biochem Pharmacol 2005;70: 481-8.
44. Cantor SB, Urano T, Feig LA. Identification and characterization of Ral-binding protein 1, a potential downstream target of Ral GTPases. Mol Cell Biol 1995;15:4578-84.
45. Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001;61: 7388-93.
46. Nizak C , Monier S, del Nery E, Moutel S, Goud B, Perez F. Recombinant antibodies to the small GTPase Rab6 as conformation sensors. Science 2003;300: 984-7.
47. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
48. Yu YP, Landsittel D, Jing L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22:2790-9.